Literature DB >> 7868407

Inhibition of the renal excretion of tazobactam by piperacillin.

M Komuro1, T Maeda, H Kakuo, H Matsushita, J Shimada.   

Abstract

A 1:4 by weight of combination of tazobactam, a new beta-lactamase inhibitor, and piperacillin, is now under development in Japan. After bolus iv administration of the combination to beagle dogs, piperacillin both significantly raised the area under plasma concentration time curve (AUC0 approximately infinity) and significantly decreased the total body clearance (Cltot) of tazobactam. The percentage binding of tazobactam and piperacillin to dog and human serum protein was the same for the combination as for the individual compounds. Piperacillin significantly decreased the renal clearance (Clr) and the clearance ratio (Cr) of tazobactam in dogs. Further, probenecid significantly decreased Clr of both tazobactam and piperacillin, and the Cr of tazobactam and piperacillin approximately reached unity. These results indicate that piperacillin inhibits the renal excretion of tazobactam. Both tazobactam and piperacillin are secreted by a tubular anion transport system which is identical to the probenecid secretion system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7868407     DOI: 10.1093/jac/34.4.555

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Authors:  Catharine C Bulik; Pamela R Tessier; Rebecca A Keel; Christina A Sutherland; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.

Authors:  Brian Vanscoy; Rodrigo E Mendes; Mariana Castanheira; Jennifer McCauley; Sujata M Bhavnani; Alan Forrest; Ronald N Jones; Olanrewaju O Okusanya; Lawrence V Friedrich; Judith Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

Review 3.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

4.  A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.

Authors:  Shamir N Kalaria; Mathangi Gopalakrishnan; Emily L Heil
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

6.  In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.

Authors:  M L Monogue; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

7.  In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.

Authors:  S M Stainton; M L Monogue; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

8.  Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.

Authors:  Adam M Blevins; Jennifer N Lashinsky; Craig McCammon; Marin Kollef; Scott Micek; Paul Juang
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

9.  Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients.

Authors:  Ibrahim El-Haffaf; Romain Guilhaumou; Lionel Velly; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2022-03-28       Impact factor: 5.577

10.  Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial.

Authors:  Jens-Ulrik Stæhr Jensen; Lars Hein; Bettina Lundgren; Morten Heiberg Bestle; Thomas Mohr; Mads Holmen Andersen; Klaus Julius Thornberg; Jesper Løken; Morten Steensen; Zoë Fox; Hamid Tousi; Peter Søe-Jensen; Anne Øberg Lauritsen; Ditte Gry Strange; Nanna Reiter; Katrin Thormar; Paul Christian Fjeldborg; Kim Michael Larsen; Niels-Erik Drenck; Maria Egede Johansen; Lene Ryom Nielsen; Christian Ostergaard; Jesper Kjær; Jesper Grarup; Jens D Lundgren
Journal:  BMJ Open       Date:  2012-03-11       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.